Cellectis S.A.
CLLS
$1.26
$0.0352.87%
Weiss Ratings | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Good | |||
Efficiency Index | Very Weak | |||
Solvency Index | Good | |||
Total Return Index | Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 3.18 | |||
Price History | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -10.36% | |||
30-Day Total Return | -19.55% | |||
60-Day Total Return | -37.25% | |||
90-Day Total Return | -33.95% | |||
Year to Date Total Return | -30.66% | |||
1-Year Total Return | -50.00% | |||
2-Year Total Return | -41.90% | |||
3-Year Total Return | -63.62% | |||
5-Year Total Return | -89.64% | |||
52-Week High % Change | -63.91% | |||
52-Week Low % Change | 0.41% | |||
Price | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $3.38 | |||
52-Week Low Price | $1.22 | |||
52-Week Low Price (Date) | Mar 06, 2025 | |||
52-Week High Price (Date) | May 06, 2024 | |||
Valuation | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 129.85M | |||
Enterprise Value | 62.98M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -1.32 | |||
Earnings Per Share Growth | -22.28% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 3.39 | |||
Price/Book (Q) | 0.94 | |||
Enterprise Value/Revenue (TTM) | 1.75 | |||
Price | $1.26 | |||
Enterprise Value/EBITDA (TTM) | -0.94 | |||
Enterprise Value/EBIT | -0.81 | |||
Market Cap Category | Micro Cap | |||
Dividends and Shares | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 100.09M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 33 1 81 69 16 00 | |||
Address | -- | |||
Website | www.cellectis.com | |||
Country | France | |||
Year Founded | 1999 | |||
Profitability | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -216.28% | |||
Profit Margin | -237.34% | |||
Management Effectiveness | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -16.09% | |||
Return on Equity | -- | |||
Income Statement | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 29.07M | |||
Total Revenue (TTM) | 36.04M | |||
Revenue Per Share | $0.36 | |||
Gross Profit (TTM) | 35.88M | |||
EBITDA (TTM) | -67.22M | |||
EBIT (TTM) | -77.96M | |||
Net Income (TTM) | -85.55M | |||
Net Income Avl. to Common (TTM) | -85.55M | |||
Total Revenue Growth (Q YOY) | 997.99% | |||
Earnings Growth (Q YOY) | -31.88% | |||
EPS Diluted (TTM) | -1.32 | |||
EPS Diluted Growth (Q YOY) | 26.77% | |||
Balance Sheet | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 159.09M | |||
Cash Per Share (Q) | $1.59 | |||
Total Current Assets (Q) | 294.43M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 129.42M | |||
Current Ratio (Q) | 1.777 | |||
Book Value Per Share (Q) | $1.29 | |||
Total Assets (Q) | 395.88M | |||
Total Current Liabilities (Q) | 165.65M | |||
Total Debt (Q) | 89.87M | |||
Total Liabilities (Q) | 266.45M | |||
Total Common Equity (Q) | 129.42M | |||
Cash Flow | CLLS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -99.80M | |||
Cash from Financing (TTM) | 127.77M | |||
Net Change in Cash (TTM) | 91.73M | |||
Levered Free Cash Flow (TTM) | -14.78M | |||
Cash from Operations (TTM) | 62.75M | |||